Study summary
An EGFR-MET antibody shrank tumors after other treatments failed
29%of left-sided tumors shrank (no prior anti-EGFR drug)
What was tested
Amivantamab, an antibody against EGFR and MET first approved for lung cancer, given alone to people with RAS/BRAF wild-type metastatic colorectal cancer after 2 to 3 earlier treatments. No comparison group.
What they found
- Tumors shrank in 29% of left-sided cancers not previously given an EGFR antibody, and in 19% to 22% of other groups.
- Rash was the most common severe side effect (7%).
What it means
Now in two phase 3 trials against cetuximab-based treatment.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.